# OnCo record b-tme-immunosuppression (bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/bottlenecks/b-tme-immunosuppression/>
  a schema:Thing ;
  onco:kind "bottleneck" ;
  schema:identifier "b-tme-immunosuppression" ;
  schema:name "Cold tumours and the immunosuppressive microenvironment"@en ;
  schema:description "Most tumours keep the immune system out or asleep, so immunotherapy helps only a minority."@en ;
  schema:url <https://onco.cc/bottlenecks/b-tme-immunosuppression/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamanetworkopen.2019.2535>, <https://doi.org/10.1038/nature21349>, <https://doi.org/10.1038/s41591-018-0014-x> ;
  onco:related <https://onco.cc/ideas/idea-immunotherapy-mss-crc/>, <https://onco.cc/ideas/idea-fap-theranostics-pancancer/>, <https://onco.cc/ideas/idea-mesothelin-car-t-regional/>, <https://onco.cc/ideas/idea-photoimmunotherapy-plus-pd1/>, <https://onco.cc/roadmaps/immunotherapy-roadmap/>, <https://onco.cc/collections/cellxgene-hca/>, <https://onco.cc/ideas/idea-bio2-trem2-myeloid-reprogramming/>, <https://onco.cc/ideas/idea-bio2-in-situ-vaccination-solid/>, <https://onco.cc/ideas/idea-bio2-oncolytic-regulated-il12/>, <https://onco.cc/ideas/idea-bio2-engineered-bacteria-payloads/>, <https://onco.cc/ideas/idea-bio2-tumour-anchored-tgfbeta-trap/>, <https://onco.cc/ideas/idea-bio2-lactate-acid-axis/>, <https://onco.cc/ideas/idea-bio2-radiotherapy-sting-fractionation/>, <https://onco.cc/ideas/idea-bio2-tertiary-lymphoid-induction/>, <https://onco.cc/ideas/idea-bio2-cxcr2-neutrophil-blockade/>, <https://onco.cc/ideas/idea-bio2-caf-subtype-assignment/>, <https://onco.cc/ideas/idea-bio2-implantable-microdevice-screen/>, <https://onco.cc/ideas/idea-bio2-vascular-normalisation-window/>, <https://onco.cc/ideas/idea-bio2-complement-c5ar-blockade/>, <https://onco.cc/ideas/idea-bio2-intracavitary-immunotherapy/>, <https://onco.cc/ideas/idea-bio2-myeloid-engager-bispecific/>, <https://onco.cc/ideas/idea-bio2-hypoxia-guided-adenosine/>, <https://onco.cc/ideas/idea-bio2-histotripsy-immune-priming/>, <https://onco.cc/ideas/idea-bio2-trained-immunity-priming/>, <https://onco.cc/ideas/idea-moon-cold-to-hot-programme/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/ovarian/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/sting-agonist/>, <https://onco.cc/technologies/oncolytic-virus/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/photoimmunotherapy/>, <https://onco.cc/technologies/single-cell-spatial/>, <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/lag3/>, <https://onco.cc/targets/tigit/>, <https://onco.cc/targets/fap/>, <https://onco.cc/targets/cd47/>, <https://onco.cc/targets/dll3/> ;
  onco:drugs <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/fap-2286/>, <https://onco.cc/drugs/intismeran-autogene/>, <https://onco.cc/drugs/autogene-cevumeran/>, <https://onco.cc/drugs/vusolimogene-oderparepvec/>, <https://onco.cc/drugs/tiragolumab/>, <https://onco.cc/drugs/magrolimab/>, <https://onco.cc/drugs/epacadostat/>, <https://onco.cc/drugs/adu-s100/> ;
  onco:companies <https://onco.cc/companies/moderna/>, <https://onco.cc/companies/biontech/>, <https://onco.cc/companies/replimune/>, <https://onco.cc/companies/10x-genomics/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/cgas-sting/> ;
  onco:terms <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/tils/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/desmoplasia/>, <https://onco.cc/terms/neoantigen/>, <https://onco.cc/terms/immunogenic-cell-death/>, <https://onco.cc/terms/abscopal-effect/> ;
  onco:trials <https://onco.cc/trials/keynote-177/>, <https://onco.cc/trials/checkmate-8hw/>, <https://onco.cc/trials/niche-2/>, <https://onco.cc/trials/napoli-3/>, <https://onco.cc/trials/interpath-001/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-haslam-jama-netw-open/>, <https://onco.cc/key-papers/paper-chen-nature/> .